1082525-64-1

Basic information

• Product Name: 1H-Indazole, 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-
• Synonyms: 1H-Indazole, 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-;1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole
• CAS NO: 1082525-64-1
• Molecular Formula: C₁₈H₂₅BN₂O₃
• Molecular Weight: 328.2137
• Mol File: 1082525-64-1.mol

Chemical Properties

• Boiling Point: 480.0±35.0 °C(Predicted)
• Appearance: /
• Density: 1.19±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 1.02±0.30(Predicted)
• CAS DataBase Reference: 1H-Indazole, 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indazole, 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-(1082525-64-1)
• EPA Substance Registry System: 1H-Indazole, 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-(1082525-64-1)

Safety Data

• Hazardous Substances Data: 1082525-64-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1H-Indazole, 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)is used as a reagent in organic synthesis for the preparation of various organic molecules. Its complex structure allows for versatile chemical reactions, making it a valuable component in the synthesis of new compounds with potential applications in different industries.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1H-Indazole, 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)may be employed as a building block for the development of pharmaceutical compounds. Its unique structure could contribute to the creation of novel drugs with specific therapeutic properties, pending further research and development.
Used in Material Science:
1H-Indazole, 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)may also find applications in material science, where its structural attributes could be leveraged to develop new materials with specialized properties. 1H-Indazole, 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-'s potential use in this field is currently under investigation, with the aim of uncovering its full capabilities.

Upstream product

• 478828-53-4 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole 
• 61676-62-8 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 110-87-2 3,4-dihydro-2H-pyran 
• 53857-57-1 5-bromo-1H-indazole 
• 583-75-5 4-Bromo-2-methylaniline 
• 24106-05-6 4'-bromo-2'-methylacetanilide 
• 120-66-1 N-(2-methylphenyl)acetamide 
• 95-53-4 o-toluidine 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1158681-06-1 C₁₉H₂₀N₂O₂ 
• 1365888-06-7 (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid 

Relevant articles and documents

Synthesis of Selective Estrogen Receptor Degrader GDC-0810 via Stereocontrolled Assembly of a Tetrasubstituted All-Carbon Olefin

We report an efficient synthesis of GDC-0810 on the basis of a sequence involving a highly stereoselective lithium tert-butoxide-mediated enolization-tosylation (≥95:5 E:Z) and a Pd-catalyzed Suzuki-Miyaura cross-coupling as key steps. Global deprotection, pyrrolidine salt formation, and final active pharmaceutical ingredient (API) form control/isolation produced GDC-0810 free acid in a 40% overall yield with >99.0% purity as ascertained by HPLC analysis.

ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS

Conjugate of a binder having formula: (A) wherein AB stands for a binder, Z' stands for a linker and D stands for an active component of Formula (I): and its use as pharmaceuticals.

PROCESS FOR THE PREPARATION OF (E)-3-(4-((E)-2-(2-CHLORO-4-FLUOROPHENYL)-1-(1H-INDAZOL-5-YL)BUT-1-EN-1-YL)PHENYL)ACRYLIC ACID

Processes are described for the preparation of estrogen receptor modulating compound, (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid (I): and salts thereof, and intermediates useful for the preparation of (I).

3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, [Formula should be inserted here] Also provided herein are pharmaceutical compositions, comprising compounds of Formula (I), and methods of

NOVEL TRIAZINE COMPOUNDS

The present invention relates to novel triazine compounds of formula (1). The present invention also discloses compounds of formula I along with other pharmaceutical ac-ceptable excipients and use of the compounds to modulate the PI3K/ mTOR pathway

PYRROLIDINYL DERIVATIVES AND USES THEREOF

The invention relates to 3,3 disubstituted pyrrole derivatives useful for treatment of diseases associated with monoamine reuptake inhibitors.Also provided pharmaceutical compositions, methods of using, and methods of preparing the compounds.